Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 23.42% | Reduce −0.9% | 3,955,000 | $26.60 | $105M | −35,000 | −$29M |
| ETON - Eton Pharmaceuticals | 8.24% | Hold | 2,852,070 | $12.98 | $37M | — | — |
| SNWV - Sanuwave Health | 7.65% | New | 972,002 | $35.37 | $34M | +972,002 | +$34M |
| LQDA - Liquidia | 7.42% | Add +33.1% | 2,260,000 | $14.75 | $33M | +561,858 | +$13M |
| RYTM - Rhythm Pharmaceuticals | 5.78% | Reduce −2.0% | 490,000 | $52.97 | $26M | −10,000 | −$2M |
| CDXS - Codexis | 5.69% | Add +7.5% | 9,500,000 | $2.69 | $26M | +660,000 | −$17M |
| Immunome | 5.32% | Add +74.0% | 3,550,000 | $6.73 | $24M | +1,510,000 | +$2M |
| TGTX - Tg Therapeutics | 4.70% | Reduce −76.3% | 535,000 | $39.43 | $21M | −1,725,000 | −$47M |
| ARVN - Arvinas | 3.09% | Add +21.5% | 1,975,000 | $7.02 | $14M | +350,000 | −$20M |
| OCUL - Ocular Therapeutix | 2.60% | Reduce −63.3% | 1,595,000 | $7.33 | $12M | −2,747,500 | −$25M |
| EWTX - Edgewise Therapeutics | 1.93% | Reduce −17.7% | 395,000 | $22.00 | $9M | −85,000 | −$4M |
| Protara Therapeutics | 1.64% | Reduce −5.2% | 1,730,000 | $4.26 | $7M | −95,000 | −$2M |
| DNA - Ginkgo Bioworks · CLASS A | 1.52% | Reduce −0.4% | 1,195,000 | $5.70 | $7M | −5,000 | −$5M |
| ANIK - Anika Therapeutics | 1.32% | New | 395,000 | $15.03 | $6M | +395,000 | +$6M |
| PTGX - Protagonist Therapeutics | 1.13% | Hold | 105,000 | $48.36 | $5M | — | — |
| XOMA - XOMA Del | 1.12% | Add +1.2% | 253,043 | $19.93 | $5M | +3,043 | −$2M |
| TRVI - Trevi Therapeutics | 1.11% | Reduce −65.7% | 795,000 | $6.29 | $5M | −1,522,500 | −$5M |
| PVLA - Palvella Therapeutics | 1.07% | New | 172,357 | $27.99 | $5M | +172,357 | +$5M |
| Gossamer Bio | 1.05% | Reduce −4.5% | 4,287,415 | $1.10 | $5M | −202,585 | +$655K |
| ANAB - Anaptys Bio | 1.04% | New | 250,933 | $18.59 | $5M | +250,933 | +$5M |
| IRON - Disc Medicine | 0.94% | New | 85,000 | $49.64 | $4M | +85,000 | +$4M |
| LRMR - Larimar Therapeutics | 0.92% | New | 1,914,077 | $2.15 | $4M | +1,914,077 | +$4M |
| CGON - Cg Oncology | 0.89% | New | 163,988 | $24.49 | $4M | +163,988 | +$4M |
| Acelyrin | 0.89% | Reduce −27.7% | 1,615,000 | $2.47 | $4M | −620,000 | −$3M |
| RCEL - Avita Medical | 0.80% | New | 440,000 | $8.14 | $4M | +440,000 | +$4M |
| Essa Pharma | 0.78% | Hold | 2,209,998 | $1.58 | $3M | — | — |
| ZNTL - Zentalis Pharmaceuticals | 0.70% | Add +12.3% | 1,985,000 | $1.59 | $3M | +217,500 | −$2M |
| Cargo Therapeutics | 0.60% | Reduce −11.1% | 666,503 | $4.07 | $3M | −83,497 | −$8M |
| Zymeworks | 0.46% | New | 175,000 | $11.91 | $2M | +175,000 | +$2M |
| Biodesix | 0.45% | Reduce −6.9% | 3,225,000 | $0.6252 | $2M | −240,000 | −$3M |
| STOK - Stoke Therapeutics | 0.44% | Add +1100.0% | 300,000 | $6.65 | $2M | +275,000 | +$2M |
| MBX - Mbx Biosciences | 0.41% | New | 250,000 | $7.38 | $2M | +250,000 | +$2M |
| Optinose | 0.39% | New | 193,039 | $9.17 | $2M | +193,039 | +$2M |
| IRD - Opus Genetics | 0.34% | New | 1,175,000 | $1.32 | $2M | +1,175,000 | +$2M |
| IBIO — | 0.34% | Hold | 375,000 | $4.02 | $2M | — | — |
| Holding · CL A | 0.31% | New | 62,501 | $22.21 | $1M | +62,501 | +$1M |
| NRIX - Nurix Therapeutics | 0.30% | Reduce −69.6% | 115,000 | $11.88 | $1M | −263,500 | −$6M |
| RZLT - Rezolute | 0.30% | Hold | 465,000 | $2.90 | $1M | — | — |
| Sangamo Therapeutics | 0.15% | New | 1,055,000 | $0.6558 | $692K | +1,055,000 | +$692K |
| PEPG - Pepgen | 0.13% | Add +281.8% | 420,000 | $1.40 | $590K | +310,000 | +$173K |
| DERM - Journey Medical | 0.09% | New | 69,323 | $5.90 | $409K | +69,323 | +$409K |
| Ventyx Biosciences | 0.05% | Reduce −32.1% | 190,000 | $1.15 | $219K | −90,000 | −$395K |
| ADGM - Adagio Med | 0.02% | Hold | 110,571 | $0.8330 | $92K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Jasper Therapeutics | 1.50% | Exit | 0 | $21.38 | $9M | −400,000 | −$9M |
| NAMS - Newamsterdam Pharma | 1.46% | Exit | 0 | $25.70 | $8M | −325,000 | −$8M |
| PCVX - Vaxcyte | 1.07% | Exit | 0 | $81.87 | $6M | −75,000 | −$6M |
| NUVL - Nuvalent | 0.80% | Exit | 0 | $78.27 | $5M | −58,500 | −$5M |
| ABCL - Abcellera Biologics | 0.49% | Exit | 0 | $2.93 | $3M | −965,000 | −$3M |
| URGN - Urogen Pharma | 0.41% | Exit | 0 | $10.65 | $2M | −220,000 | −$2M |
| Immatics | 0.21% | Exit | 0 | $7.11 | $1M | −165,000 | −$1M |
| LXEO - Lexeo Therapeutics | 0.15% | Exit | 0 | $6.58 | $855K | −130,000 | −$855K |
| REGENXBIO | 0.11% | Exit | 0 | $7.72 | $618K | −80,000 | −$618K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2